Invivyd, Inc.
Quick facts
Phase 3 pipeline
- VYD222 (pemivibart) · Infectious Disease
VYD222 (pemivibart) is an investigational antiviral medication that works by inhibiting the replication of SARS-CoV-2. - VYD2311-MD · Infectious Disease
VYD2311-MD is a monoclonal antibody that targets the SARS-CoV-2 spike protein. - VYD2311-SD · Infectious Disease
VYD2311-SD is a COVID-19 vaccine.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Invivyd, Inc.
What is Invivyd, Inc.'s pipeline?
Invivyd, Inc. has 3 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include VYD222 (pemivibart), VYD2311-MD, VYD2311-SD.
Related
- Sector hub: All tracked pharma companies